Leukocyte adherence inhibition responses obtained with various tumor extracts in breast cancer patients.
Leukocyte adherence inhibition (LAI) assay was employed to detect cell-mediated immune response in breast cancer patients of clinical stages I and II. Twenty-one breast cancer extracts were screened in 232 breast cancer patients and 343 healthy persons. The activity of individual extracts differed remarkably. Overall, LAI response was 58.6% (136/232) correct and 18.9% (65/343) false positive. Fifteen extracts were not suitable from the clinical point of view. Only two extracts gave a constantly high rate of tumor-specific LAI-positive values in breast cancer patients, ie, 83.3% (25/30) and low percentage of false positive results in controls, ie, 4% (2/50). A further study dealt with the possible relation between the activity of extracts (expressed in percentage of positive LAI results in the tumor group) and histology of primary tumor of patients whose tumor tissue was used for extraction. This relationship could not be proven statistically. We investigated also whether the percentage of correct LAI responses in breast cancer patients could be affected by histological agreement or disagreement (grading and node involvement) between primary tumor of extract donor and primary tumor of patients tested. No significant relationship was found in this respect.
D000328:Adult; D001943:Breast Neoplasms / Q000276:immunology*; D005260:Female; D006801:Humans; D007158:Immunologic Techniques; D007957:Leukocyte Adherence Inhibition Test; D008875:Middle Aged